Orbimed Advisors LLC Chemomab Therapeutics Ltd. Put Options Transaction History
Orbimed Advisors LLC
- $2.8 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CMMB
# of Institutions
14Shares Held
4.22MCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY1.61MShares$4.96 Million0.0% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L3738KShares$2.27 Million0.24% of portfolio
-
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L3578KShares$1.78 Million0.12% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$654,0690.08% of portfolio
-
Rhumbline Advisers Boston, MA39.9KShares$122,4160.0% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $35.1M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...